Published in Dig Dis Sci on January 01, 2002
Upper gastrointestinal ulcer in Japanese patients taking low-dose aspirin. J Gastroenterol (2009) 1.10
The preventive factors for aspirin-induced peptic ulcer: aspirin ulcer and corpus atrophy. J Gastroenterol (2009) 0.91
Prospective multi-center trial for the efficacy of ecabet sodium on the relief of dyspepsia in korean patients with chronic gastritis. J Clin Biochem Nutr (2007) 0.75
Investigation of Gastroduodenal Mucosal Injury in Japanese Asymptomatic Antiplatelet Drug Users. Medicine (Baltimore) (2015) 0.75
Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev (1991) 42.38
Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1995) 9.77
Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med (1999) 8.60
Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet (1994) 6.89
Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet (1994) 6.40
Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med (1998) 4.24
A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med (1998) 3.96
Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci U S A (1993) 3.93
Helicobacter pylori induced interleukin-8 expression in gastric epithelial cells is associated with CagA positive phenotype. J Clin Pathol (1995) 3.86
Interobserver variation in the histopathological assessment of Helicobacter pylori gastritis. Hum Pathol (1996) 3.57
Induction of various cytokines and development of severe mucosal inflammation by cagA gene positive Helicobacter pylori strains. Gut (1997) 3.39
Interleukin-8 expression in Helicobacter pylori infected, normal, and neoplastic gastroduodenal mucosa. J Clin Pathol (1994) 3.16
Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med (1989) 2.88
Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci U S A (1992) 2.55
A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology (1995) 2.30
Towards a better aspirin. Nature (1994) 2.20
Chemokines in the gastric mucosa in Helicobacter pylori infection. Gut (1998) 2.07
Role of nitric oxide in gastrointestinal and hepatic function and disease. Gastroenterology (1992) 2.04
Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology (1999) 2.04
Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl (1999) 1.97
The physiology of gastric acid secretion. N Engl J Med (1988) 1.85
COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol Suppl (1997) 1.82
Relation between clinical presentation, Helicobacter pylori density, interleukin 1beta and 8 production, and cagA status. Gut (1999) 1.72
Mechanisms underlying gastric mucosal damage induced by indomethacin and bile-salts, and the actions of prostaglandins. Br J Pharmacol (1977) 1.68
Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial. Ann Intern Med (1991) 1.68
Interaction between Helicobacter pylori and non-steroidal anti-inflammatory drugs in peptic ulcer bleeding. Scand J Gastroenterol (1999) 1.61
Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. J Clin Invest (1995) 1.55
Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a case-control study. Gastroenterology (1999) 1.54
Helicobacter pylori infection reduces intraluminal nitric oxide in humans. J Gastroenterol (1999) 1.47
Aspirin-induced gastritis, like Helicobacter pylori-induced gastritis disinhibits acid secretion in humans: relation to cytokine expression. Scand J Gastroenterol (1998) 1.46
Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: where we stand. Am J Gastroenterol (1996) 1.44
The discovery and function of COX-2. J Rheumatol Suppl (1997) 1.39
Endothelium-derived relaxing factor (nitric oxide) has protective actions in the stomach. Life Sci (1989) 1.19
Relationship between Campylobacter pylori and gastritis in healthy humans after administration of placebo or indomethacin. Gastroenterology (1988) 1.19
Intrinsic source of stomach NO. Nature (1994) 1.09
Peptic ulcer bleeding in the elderly: relative roles of Helicobacter pylori and non-steroidal anti-inflammatory drugs. Gut (1997) 1.05
Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut (1993) 1.03
Endoscopic comparison of cimetidine and sucralfate for prevention of naproxen-induced acute gastroduodenal injury. Effect of scoring method. Dig Dis Sci (1990) 1.01
Correlation of mucosal histology and aspirin intake in chronic gastric ulcer. Gastroenterology (1973) 0.96
Prevention of gastroduodenal injury induced by chronic nonsteroidal antiinflammatory drug therapy. Gastroenterology (1989) 0.90
Non-steroidal anti-inflammatory drug gastropathy and cytoprotection: pathogenesis and mechanisms re-examined. Scand J Gastroenterol Suppl (1992) 0.89
Neutrophils, Helicobacter pylori, and nonsteroidal anti-inflammatory drug ulcers. Gastroenterology (1999) 0.89
Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: a controlled double-blind trial. Aliment Pharmacol Ther (1995) 0.86
A randomized double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production. Gastrointest Endosc (1995) 0.86
Alendronate gastric ulcers. Aliment Pharmacol Ther (1999) 0.85
Personal review: Helicobacter pylori, NSAIDs and cognitive dissonance. Aliment Pharmacol Ther (1999) 0.83
Gastroduodenal mucosal prostaglandin generation in patients with Helicobacter pylori before and after treatment with bismuth subsalicylate. Dig Dis Sci (1991) 0.80
Influence of Helicobacter pylori on gastric mucosal adaptation to naproxen in man. Dig Dis Sci (1996) 0.79
Cytokines as biological response modifiers. J Clin Pathol (1992) 0.79
Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomized study. Aliment Pharmacol Ther (1998) 0.79
Helicobacter pylori infection reduces intraluminal nitric oxide. Scand J Gastroenterol (2000) 0.77
Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut (2012) 12.62
Traces of human migrations in Helicobacter pylori populations. Science (2003) 11.92
Norwalk virus infection and disease is associated with ABO histo-blood group type. J Infect Dis (2002) 5.09
Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med (2011) 3.78
Norwalk virus shedding after experimental human infection. Emerg Infect Dis (2008) 3.70
Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology (2006) 3.68
Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol (2005) 3.34
Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. Gastroenterology (2002) 3.27
The peopling of the Pacific from a bacterial perspective. Science (2009) 3.14
ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc (2006) 3.12
Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score. J Clin Gastroenterol (2012) 2.99
Gastroesophageal reflux among different racial groups in the United States. Gastroenterology (2004) 2.87
Age at acquisition of Helicobacter pylori infection: a follow-up study from infancy to adulthood. Lancet (2002) 2.71
ASGE guideline: colorectal cancer screening and surveillance. Gastrointest Endosc (2006) 2.63
Gain and loss of multiple genes during the evolution of Helicobacter pylori. PLoS Genet (2005) 2.61
Helicobacter pylori in North and South America before Columbus. FEBS Lett (2002) 2.57
Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol (2005) 2.54
Determination of the 50% human infectious dose for Norwalk virus. J Infect Dis (2013) 2.50
Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl (2005) 2.43
A report card to grade Helicobacter pylori therapy. Helicobacter (2007) 2.41
Prevalence of Helicobacter pylori infection in long-term hemodialysis patients. Kidney Int (2008) 2.39
ASGE guideline: The role of endoscopy in acute non-variceal upper-GI hemorrhage. Gastrointest Endosc (2004) 2.33
Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. Gastroenterology (2002) 2.32
Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis (2010) 2.21
Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol (2009) 2.15
Regulation of gastric carcinogenesis by Helicobacter pylori virulence factors. Cancer Res (2008) 2.08
Comparing the Blatchford and pre-endoscopic Rockall score in predicting the need for endoscopic therapy in patients with upper GI hemorrhage. Gastrointest Endosc (2010) 2.04
Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology (2005) 2.03
Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer (2004) 2.03
Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter (2009) 2.02
Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter (2011) 2.00
Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol (2011) 1.98
Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res (2008) 1.91
Contribution of bone marrow cells to liver regeneration after partial hepatectomy in mice. J Hepatol (2002) 1.91
Gastritis staging in clinical practice: the OLGA staging system. Gut (2006) 1.90
Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg (2007) 1.82
Effects of Helicobacter pylori eradication on methylation status of E-cadherin gene in noncancerous stomach. Clin Cancer Res (2006) 1.79
A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication. Am J Gastroenterol (2005) 1.79
Report of the 15th follow-up survey of primary liver cancer. Hepatol Res (2004) 1.78
Risk factors for immediate and delayed bleeding associated with endoscopic submucosal dissection of gastric neoplastic lesions. Scand J Gastroenterol (2009) 1.75
NSAIDs, Helicobacter pylori, and Pandora's Box. N Engl J Med (2002) 1.75
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter (2011) 1.73
Discrimination between cases of duodenal ulcer and gastritis on the basis of putative virulence factors of Helicobacter pylori. J Clin Microbiol (2002) 1.72
Patterns of gastric atrophy in intestinal type gastric carcinoma. Cancer (2002) 1.69
Biliary stenting in the management of large or multiple common bile duct stones. Gastrointest Endosc (2010) 1.68
Esophageal dilation. Gastrointest Endosc (2006) 1.68
Management of gastric polyps: a pathology-based guide for gastroenterologists. Nat Rev Gastroenterol Hepatol (2009) 1.62
Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res (2004) 1.60
Role of interferon-stimulated responsive element-like element in interleukin-8 promoter in Helicobacter pylori infection. Gastroenterology (2004) 1.59
Helicobacter pylori infection in mice: Role of outer membrane proteins in colonization and inflammation. Gastroenterology (2002) 1.58
Iron deficiency and Helicobacter pylori infection in the United States. Am J Epidemiol (2005) 1.57
Endoscopic demonstration of transient small bowel intussusception in a patient with adult celiac disease. Gastrointest Endosc (2003) 1.55
Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery (2005) 1.54
Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol (2005) 1.53
c-Src and c-Abl kinases control hierarchic phosphorylation and function of the CagA effector protein in Western and East Asian Helicobacter pylori strains. J Clin Invest (2012) 1.53
Helicobacter pylori-negative gastritis: prevalence and risk factors. Am J Gastroenterol (2012) 1.51
Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs (2008) 1.48
Horizontal versus familial transmission of Helicobacter pylori. PLoS Pathog (2008) 1.48
Helicobacter pylori eradication and change in markers of iron stores among non-iron-deficient children in El Paso, Texas: an etiologic intervention study. J Pediatr Gastroenterol Nutr (2011) 1.47
Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg (2002) 1.47
Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23,040 genes. Cancer Res (2002) 1.46
Helicobacter pylori virulence factors: facts and fantasies. Curr Opin Gastroenterol (2005) 1.44
Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg (2005) 1.44
The relationship between Helicobacter pylori infection and Alzheimer's disease in Japan. J Neurol (2011) 1.44
Molecular epidemiology, population genetics, and pathogenic role of Helicobacter pylori. Infect Genet Evol (2011) 1.44
Etest for metronidazole susceptibility in H. pylori: use of the wrong standard may have led to the wrong conclusion. Am J Gastroenterol (2004) 1.43
Perioperative changes in carbonylhemoglobin and methemoglobin during abdominal surgery: alteration in endogenous generation of carbon monoxide. J Gastroenterol Hepatol (2002) 1.43
Effect of the carbonic anhydrase inhibitor, acetazolamide, on Helicobacter pylori infection in vivo: a pilot study. Helicobacter (2005) 1.42
Analysis of Helicobacter pylori genotypes and correlation with clinical outcome in Turkey. J Clin Microbiol (2004) 1.42
Waist-to-hip ratio, but not body mass index, is associated with an increased risk of Barrett's esophagus in white men. Clin Gastroenterol Hepatol (2012) 1.41
Expression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during Helicobacter pylori infection. J Immunol (2006) 1.41
Double-blind randomized trial of quadruple sequential Helicobacter pylori eradication therapy in asymptomatic infected children in El Paso, Texas. J Pediatr Gastroenterol Nutr (2011) 1.40
Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology (2002) 1.39
Helicobacter pylori infection--a boon or a bane: lessons from studies in a low-prevalence population. Helicobacter (2013) 1.38
Association between Helicobacter pylori virulence factors and gastroduodenal diseases in Okinawa, Japan. J Clin Microbiol (2011) 1.37
Regulation of interleukin-6 promoter activation in gastric epithelial cells infected with Helicobacter pylori. Mol Biol Cell (2005) 1.37
ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. Gastrointest Endosc (2006) 1.36
Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med (2002) 1.35
Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg (2002) 1.35
Molecular epidemiology and outcome of Helicobacter pylori infection in Thailand: a cultural cross roads. Helicobacter (2004) 1.35
A comprehensive sequence and disease correlation analyses for the C-terminal region of CagA protein of Helicobacter pylori. PLoS One (2009) 1.34
Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat. Gastroenterology (2003) 1.34
Clinical presentation in relation to diversity within the Helicobacter pylori cag pathogenicity island. Am J Gastroenterol (2002) 1.34
ASGE guideline: complications of EUS. Gastrointest Endosc (2005) 1.32
Antimicrobial activity of essential oils against Helicobacter pylori. Helicobacter (2003) 1.31
Diagnosis and management of iron deficiency anemia in the 21st century. Therap Adv Gastroenterol (2011) 1.30
Helicobacter pylori infection in Kazakhstan: effect of water source and household hygiene. Am J Trop Med Hyg (2002) 1.29
Eradication of gastric cancer is now both possible and practical. Semin Cancer Biol (2013) 1.28
Involvement of PEG10 in human hepatocellular carcinogenesis through interaction with SIAH1. Cancer Res (2003) 1.28